Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020
July 28, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
May 29, 2020 08:30 ET
|
Paratek Pharmaceuticals
BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference
May 28, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
May 11, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
May 11, 2020 06:30 ET
|
Paratek Pharmaceuticals
-- Announced Initiation of Funding from BARDA for All FDA Required Post-Marketing Studies and Security Requirements and U.S. Onshoring of an Additional Manufacturing Supply Chain for...
Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020
April 30, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)
April 02, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)
April 01, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)
March 10, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 02, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...